Kinetic characterization of secretory transport of a new ciprofloxacin derivative (CNV97100) across Caco-2 cell monolayers

Journal of Pharmaceutical Sciences

Volumn 91, Issue 12, 2002, Pages 2511-2519

  Ruiz García, Ana ^a,b   Lin, Huimin ^a   Plá Delfina, José M ^b   Hu, Ming ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Caco 2; Cell culture model; Ciprofloxacin; CNV 97100; Cyclosporin A; Efflux; Indomethacin; Kinetics; Leukotriene C4; P glycoprotein multidrug resistance related protein (MRP); Quinidine; Verapamil

Indexed keywords

CIPROFLOXACIN; CNV 97100; CNV 97101 104; CYCLOSPORIN A; GLYCOPROTEIN; LEUKOTRIENE C4; MULTIDRUG RESISTANCE PROTEIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG; VERAPAMIL; ANTIINFECTIVE AGENT; CARRIER PROTEIN; CNV9710; DRUG DERIVATIVE;

ALKYLATION; CELL MEMBRANE TRANSPORT; CELL STRAIN CACO 2; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG ELIMINATION; DRUG PENETRATION; DRUG STRUCTURE; DRUG TRANSPORT; HUMAN; HUMAN CELL; MONOLAYER CULTURE; TEMPERATURE DEPENDENCE; ACTIVE TRANSPORT; ARTICLE; CHEMISTRY; METABOLISM; PHARMACOKINETICS; PHYSIOLOGY;

ANTI-INFECTIVE AGENTS; BIOLOGICAL TRANSPORT, ACTIVE; CACO-2 CELLS; CIPROFLOXACIN; HUMANS; MEMBRANE TRANSPORT PROTEINS; PHARMACOKINETICS;

EID: 0036891907     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10244     Document Type: Conference Paper

References (44)

1. Updated recommendations for antimicrobial prophylaxis among asymptomatic pregnant women after exposure to Bacillus anthracis. MMWR Morb Mortal Wkly Rep 2001 Nov 2, 50(43):960.
2. Domagala JM. 1994. Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J Antimicrob Chemother 33:685-706.
3. Mitscher LA, Zavod RM, Sharma PN. 1989. Structure-activity relationships of the newer quinolone antibacterial agents. In: Fernandes PB, editor. Quinolones. Prous Science. p. 3-20, Barcelona, Spain.
4. Neuman M. 1988. Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet 14:96-121.
5. Freeman CD, Nicolau DP, Belliveau PP, Nightingale CH. 1993. Lomefloxcin clinical pharmacokinetics. Clin Pharmacokinet 25:6-19.
6. Goa KL, Bryson HM, Markhan A. 1997. Sparfloxacin. Drugs 53:700-725.
7. Griffiths NM, Hirst BH, Simmons NL. 1994. Active intestinal secretion of the fluoroquinolone antibacterials ciprofloxacin, norfloxacin and pefloxacin; a common secretory pathway? Pharmacol Exp Ther 269:496-502.
8. Rubistein E, Dautrey S, Farinotti R, St Julien L, Ramon J, Carbon C. 1995. Intestinal elimination of sparfloxacin, fleroxacin and ciprofloxacin in rats. Antimicrob Agents Chemother 39:99-102.
9. Roehwedder R, Bergan T, Thorsteinsson SB, Scholl H. 1990. Transintestinal elimination of ciprofloxacin. Chemotherapy 36:77-84.
10. Cormet-Boyaka E, Huneau JF, Mordrelle A, Boyaka PN, Carbon C, Rubistein E, Tome D. 1998. Secretion of Sparfloxacin from the human intestinal Caco-2 cell line is altered by p-glycoprotein inhibitors. Antimicrob Agents Chemother 42:2607-2611.
11. Naruhashi K, Tamai I, Inoue N, Muraoka H, Sai Y, Suzuki N, Tsuji A. 2001. Active intestinal secretion of new quinolone antimicrobials and the partial contribution of P-glycoprotein. J Pharm Pharmacol 53:699-709.
12. Griffiths NM, Hirst BH, Simmons NL. 1993. Active secretion of the fluoroquinolone ciprofloxacin by human intestinal epithelial Caco-2 cell monolayers. Br J Pharmacol 1088:575-576.
13. Cavet ME, West M, Simmons NL. 1997. Fluoroquinolone (ciprofloxacin) secretion by human intestinal epithelial (Caco-2) cells. Br J Pharmacol 121:1567-1578.
14. Ramon J, Dautrey S, Farinotti R, Carbon C, Rubistein E. 1994. Intestinal elimination of ciprofloxacin in rabbits. Antimicrob Agents Chemother 38:757-760.
15. Rubistein E, Julien ST, Ramon J, Dautrey S, Farinotti R, Huneau JF, Carbon C. 1994. The intestinal elimination of ciprofloxacin in the rat. J Infect Dis 169:218-221.
16. Dautrey S, Felice K, Petiet A, Lacour B, Carbon C, Farinotti R. 1999. Active intestinal elimination of ciprofloxacin in rats: Modulation by different substrates. Br J Pharmacol 127:1728-1734.
17. Hu M, Chen J, Tran D, Zhu Y, Leonardo G. 1994. The Caco-2 cell monolayers as an intestinal metabolism model: Metabolism of dipeptide Phe-Pro. J Drug Targeting 2:79-89.
18. Hu M, Chen J, Zhu Y, Dantzing AH, Stratford RE Jr, Kuhfeld MT. 1994. Mechanism and kinetics of transcellular transport of a new β-lactam antibiotic loracarbef across a human intestinal epithelial model system (Caco-2). Pharm Res 11:1405-1413.
19. Hidalgo IJ, Raub TJ, Borchadt RT. 1989. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 96:736-749.
20. Powell DW. 1987. Johnson LR, editor. Physiology of the Gastrointestinal Tract. 2nd Ed. New York: Raven Press. pp. 1267-1305.
21. Hofer M, Hoggett JG. 1981. Transport Across Biological Membranes. Boston: Pitman. p. 96.
22. Choo EF, Leake B, Wandel C, Imamura H, Wood AJJ, Wilkinson GR, Kim RB. 2000. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitor into brain and testes. Drug Metab Dispos 28(6):655-660.
23. Lennernas H. 1997. Human jejunal effective permeability and its correlation with preclinical drug absorption models. J Pharm Pharmacol 49:627-638.
24. Karlsson J, Kuo SM, Ziemniak J, Artursson P. 1993. Transport of celiprolol across human intestinal epithelial (Caco-2) cells: Mediation of secretion by multiple transporters including P-glycoprotein. Br J Pharmacol 110:1009-1016.
25. Eneroth A, Aström E, Hoogstraate J, Schrenk D, Conrad S, Kauffmann HM, Gjellan K. 2001. Evaluation of a vincristine resistant Caco-2 cell line for use in a calcein AM extrusion screening assay for P-glycoprotein interaction. Eur J Pharm Sci 12:205-214.
26. Huai-Yun H, Secrest DT, Mark KS, Carney D, Brandquist C, Elquimst WF, Miller DW. 1998. Expression of multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells. Biochem Biophys Res Commun 243:816-820.
27. Kiuchi Y, Suzuki H, Hisohashi T, Tyson CA, Sugiyama Y. 1998. CDNA cloning and inducible expression of human multidrug resistance associated protein 3 (MRP3). FEBS Lett 433:149-152.
28. Hadjiagapiou C, Schmidt L, Dudeja PK, Layden TJ, Ramaswamy K. 2000. Mechanism(s) of butyrate transport in Caco-2 cells: Role of monocarboxylate transporter 1. Am J Physiol Gastrointest Liver Physiol 279:G775-780.
29. Wain HM, White JA, Povey S. 1999. Proposed nomenclature for the human ABC genes, based on sub-family assignments. 2nd FEBS Advanced Lecture Course, Abstract number 20.
30. Wain H, White J, Povey S. 1999. The changing challenges of nomenclature. Cytogenet Cell Genet 86:162-164.
31. White J, Wain H, Bruford E, Povey S. 1999. Promoting a standard nomenclature for genes and proteins. Nature 25 402:347.
32. Mottino AD, Hoffman T, Jennes L, Vore M. 2000. Expression and localization of multidrug resistant protein mrp2 in rat small intestine. J Pharmacol Exp Ther 293(3):717-723.
33. Tsuji A, Tamai I. 1996. Carrier-mediated intestinal transport of drugs. Pharm Res 13:963-977.
34. Fricker G, Drewe J, Huwyler J, Gutmann H, Beglinger C. 1996. Relevance of P-glycoprotein for the enteral absorption of cyclosporin A: In vitro-in vivo correlation. Br J Pharmacol 118:1841-1847.
35. Saitoh H, Aungst BJ. 1995. Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine. Pharm Res 12:1304-1310.
36. Karlsson J, Shiu-Ming K, Ziemniak J, Artursson P. 1993. Transport of celiprolol across human intestinal epithelial (Caco-2) cells: Mediation of secretion by multiple transporters including P-glycoprotein. Br J Pharmacol 110:1009-1016.
37. Wang Q, Yang H, Miller DW, Elmquist WF. 1995. Effect of the P-glycoprotein inhibitor Cyclosporine A on the distribution of rhodamine-123 to the brain: An in vivo microdialysis study in freely moving rats. Biochem Biophys Res Commun 211:719-726.
38. 4 and chemotherapeutic agents in membrane vesicles. J Biol Chem 271:9675-9682.
39. 4 and structurally related conjugates. J Biol Chem 269:27807-27810.
40. Dantzig AH, Shepard RL, Law KL, Tabas L, Pratt S, Gillespie JS, Binkley SN, Kuhfeld MT, Starling JJ, Wrighton SA. 1999. Selectivity of the multidrug resistance modulator LY-335979, for P-glycoprotein and effect on cytochrome P-450 activities. J Pharm Exp Ther 290:854-862.
41. Markhey VD, Guo A, Norris DA, Hu P, Yan J, Sinko PJ. 1998. Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in caco-2 cells. Pharm Res 15:1160-1167.
42. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJJ, Roden DM, Wilkinson GR. 1998. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101:289-294.
43. Dixon and Webb. 1979. Enzymes, 3rd Ed. New York: Academic Press. pp. 332-467.
44. Shapiro AB, Fox K, Lam P, Ling V. 1999. Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Eur J Biochem 259:841-850.